Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John Scopes is active.

Publication


Featured researches published by John Scopes.


British Journal of Haematology | 1994

Haemopoietic progenitor cells are reduced in aplastic anaemia

John Scopes; Maree Bagnara; Edward C. Gordon-Smith; Sarah E. Ball; Frances M. Gibson

Summary We investigated the frequencies of early populations of progenitors in aplastic anaemia (AA) bone marrow, from patients with a range of disease severity, compared with normal. Double‐colour immunofluorescent staining for CD34 and CD33 was carried out on bone marrow mononuclear cells (BMMC) and analysed using fluorescence activated cell sorting (FACS), AA CD34+ cells were reduced by 68% compared to normal. In addition, AA CD33+ cells and the three progenitor subsets (CD34+/CD33–, CD34+/CD33+ and CD34–/CD33+) were reduced by 44–80%. Our data lend further support for an early stem cell deficiency in AA.


British Journal of Haematology | 1994

Aplastic anaemia following exposure to 3,4‐methylenedioxymethamphetamine (‘Ecstasy’)

J. C. W. Marsh; Z. H. Abboudi; Frances M. Gibson; John Scopes; S. Daly; D. F. O'Shaunnessy; A. S. J. Baughan; Edward C. Gordon-Smith

Summary. We report two cases of aplastic anaemia following exposure to ‘Ecstasy’ (MDMA, 3,4‐methylenedioxymethamphetamine). In both cases the aplastic anaemia resolved spontaneously 7–9 weeks after presentation. Long‐term bone marrow culture study of one patient demonstrated complete normalization of haemopoiesis at time of haematological recovery, suggesting either that damage to the haemopoietic stem cell had been only transient, or that a more mature, committed progenitor cell was the target. Because MDMA may have been a factor in the aetiology of the bone marrow suppression in these two cases, we recommend close haematological monitoring of young adults presenting with toxicity from MDMA, and a detailed history of exposure to recreational drugs in all new patients presenting with aplastic anaemia.


British Journal of Haematology | 2001

Correction of stromal cell defect after bone marrow transplantation in aplastic anaemia

John Scopes; M. Ismail; Karen J. Marks; T. R. Rutherford; Gwen S. Draycott; Christopher Pocock; Edward C. Gordon-Smith; Frances M. Gibson

Defects in stromal cell function have been demonstrated in a number of aplastic anaemia (AA) patients. Here we have studied a patient with severe AA and abnormal stromal cell function who underwent bone marrow transplantation (BMT). The objective of this study was to investigate the timing and the mechanism of correction of the stromal defect after transplantation. The patient, a 25‐year‐old woman with severe AA, underwent BMT from her brother. BM was obtained from the patient on five occasions: 2 weeks pre BMT, and 3, 8, 16 and 21 months post BMT. Stromal cells were grown to confluence and recharged with purified CD34+ cells from normal donors. The support of such cells, as assessed by weekly colony‐forming assay (CFU) of non‐adherent cells, was compared with that of stromal layers grown from normal BM. A novel technique of combined fluorescence in situ hybridization (FISH) and immunocytochemistry was used to determine the origin of specific stromal cell types on cytospins of stroma post BMT. Stromal function was defective at 2 weeks pre BMT and at 3 months post BMT, but returned to normal at 8 and 16 months post BMT. At 21 months post BMT, stromal fibroblasts and endothelial cells were shown to be of recipient origin, and macrophages and T cells were of donor origin. We present here evidence in a case of severe AA for defective stromal function before BMT and delayed normalization of function after BMT. This correlated with engraftment of donor macrophages and T cells, but not fibroblasts and endothelial cells.


British Journal of Haematology | 1995

Haemopoietic growth factor production by normal and aplastic anaemia stroma in long‐term bone marrow culture

Frances M. Gibson; John Scopes; S. Daly; Sarah E. Ball; Edward C. Gordon-Smith

Summary. Defective marrow stroma, or microenvironment, have been proposed as one of several mechanisms to account for bone marrow failure in aplastic anaemia (AA). This could involve defects in positive‐ or negative‐acting haemopoietic regulator expression by AA stroma, or alteration of normal stroma‐stem cell interactions.


The Journal of Infectious Diseases | 1997

Human Immunodeficiency Virus Infection Impairs Hemopoiesis in Long-Term Bone Marrow Cultures: Nonreversal by Nucleoside Analogues

Vikki Gill; Robin J. Shattock; John Scopes; Peter Hayes; Andrew R. Freedman; George E. Griffin; Edward C. Gordon Smith; Frances M. Gibson

Hematologic abnormalities are often seen in patients infected with human immunodeficiency virus (HIV). The effect of HIV infection of bone marrow stroma on support of uninfected CD34 progenitor cells in long-term bone marrow culture (LTBMC) was investigated. Results show that HIV-infected bone marrow stroma was unable to adequately support CD34 progenitor cells in vitro. Zidovudine or didanosine was added to cultures in an attempt to reverse the suppressive effects exerted by HIV and to determine whether such suppression was mediated by transfer of HIV infection to progenitor cells. Didanosine failed to reduce the suppressive effects of HIV, whereas zidovudine compounded the observed suppression. HIV infection of bone marrow stroma, while reducing the production of nonadherent cells, did not increase apoptosis and cell death in such cells. In contrast, zidovudine enhanced apoptosis and cell death in nonadherent cells produced by both HIV-infected and control LTBMC.


British Journal of Haematology | 1995

IL-3 is produced by normal stroma in leng-term bone marrow cultures

Frances M. Gibson; John Scopes; S. Daly; Siân Rizzo; Sarah E. Ball; Edward C. Gordon-Smith

Summary. Interleukin‐3 (IL‐3) has been shown to have significant effects on haemopoiesis in vitro, but early investigations of normal human long‐term bone marrow cultures (LTBMC) have failed to demonstrate LL‐3 production by stromal cells, either by Northern blotting for mRNA, or assaying for bioactivity in culture supernatants. One recent report, using reverse transcription‐polymerase chain reaction (RT‐PCR), demonstrated IL‐3 expression in only one of eight cultures.


British Journal of Haematology | 1995

The effect of human flt-3 ligand on committed progenitor cell production from normal, aplastic anaemia and Diamond-Blackfan anaemia bone marrow.

John Scopes; Stephen Daly; Sarah E. Ball; Colin P. McGockin; Edward C. Gordon-Smith; Frances M. Gibson

Summary. We investigated the effect of the human ligand for flt‐3 (FL) on the committed progenitor colony formation of normal bone marrow (BM) (n = 9) and BM from four aplastic anaemia (AA) and three Diamond‐Blackfan anaemia (DBA) patients. Methylcellulose committed progenitor cell assays were carried out using FL alone and in combinations with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). interleukin‐3 (IL‐3) and c‐kit ligand (KL). FL alone had a limited, though significant, effect on the production of granulocyte‐macrophage colony‐forming unit (CFU‐GM) colonies from normal BM and showed an additive effect with IL‐ 3 and GM‐CSF separately, but not in combination. FL did not increase the stimulation of KL and did not have an effect on the production of erythroid progenitor colonies. FL had no effect on the AA and DBA BMs studied.


Experimental Hematology | 1995

INCREASED APOPTOSIS IN APLASTIC ANEMIA BONE MARROW PROGENITOR CELLS : POSSIBLE PATHOPHYSIOLOGIC SIGNIFICANCE

N. J. Philpott; John Scopes; J. C. W. Marsh; Edward C. Gordon-Smith; Frances M. Gibson


Hematology Journal | 2002

Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow.

Sian Rizzo; John Scopes; Modupe Elebute; Helen A. Papadaki; Edward C. Gordon-Smith; Frances M. Gibson


Experimental Hematology | 1994

In vitro response of normal and aplastic anemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3.

Frances M. Gibson; John Scopes; Daly S; Ball Se; Edward C. Gordon-Smith

Collaboration


Dive into the John Scopes's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Daly

St George's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge